UBC

Executive Summary

UBC is a Swiss-based company founded in 2019 that partners with biopharma to modernize patient access and evidence generation for specialty therapies. By integrating real-world evidence, risk management, and deep patient journey insights, UBC helps ensure therapies are safe, effective, and commercially viable. The company's customized solutions address the growing demand for patient-centric, data-driven approaches in an era of rising healthcare costs and regulatory focus on value demonstration. With its unique combination of services—spanning from access pathway design to safety surveillance—UBC positions itself as a strategic enabler for biopharma companies seeking to optimize launch success and long-term product value. As a private company operating in the competitive drug delivery and biologics ecosystem, UBC's growth hinges on expanding its client base and service breadth. The company is well-placed to capture market share as biopharma companies increasingly outsource patient support and evidence generation activities. Potential catalysts include new partnerships with large pharmaceutical firms, geographic expansion beyond Europe, and the development of proprietary technology platforms for real-world data collection. Given its early stage and reliance on partnership-driven revenue, UBC's near-term trajectory will depend on its ability to demonstrate tangible outcomes for clients and secure strategic collaborations.

Upcoming Catalysts (preview)

• Q4 2026Major partnership with a top-20 pharma for patient support program60% success
• H1 2027Launch of a new digital platform for real-world evidence collection50% success
• 2027Expansion into the U.S. market via strategic alliance40% success